Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Nabriva Therapeutics AG ADR buy melinda

Start price
?8.75
11.05.17 / 50%
Target price
€10.37
17.05.17
Performance (%)
4.59%
End price
€9.15
17.05.17
Summary
This prediction ended on 17.05.17 with a price of €9.15. With a performance of 4.59%, the BUY prediction by melinda for Nabriva Therapeutics AG ADR closed with a slight gain. melinda has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Nabriva Therapeutics AG ADR - - - -
iShares Core DAX® 1.662% 4.835% 17.361% 19.329%
iShares Nasdaq 100 0.667% 0.000% 38.234% 55.157%
iShares Nikkei 225® -2.139% -4.786% 13.099% 7.393%
iShares S&P 500 0.564% 0.775% 29.181% 46.527%

Comments by melinda for this prediction

In the thread Nabriva Therapeutics AG ADR diskutieren
Prediction Buy
Perf. (%) 4.59%
Target price 10.373
Change
Ends at 17.05.17

Biopharma



Nabriva Therapeutics AG ist eine klinische Phase - biopharmazeutisches beschäftigt company.It in der Forschung und Entwicklung neuer Antibiotika zur Behandlung von Infektionen, mit einem Schwerpunkt auf der Pleuromutilin Klasse von antibiotics.The Firmengründung von Rodger Novak im Oktober 2005 und hat seinen Hauptsitz in Vienn


Prediction Buy
Perf. (%) 4.59%
Target price 10.373
Change
Ends at 17.05.17

(Vom Mitglied beendet)

Stopped prediction by melinda for Nabriva Therapeutics AG ADR

buy
Nabriva Therapeutics AG ADR

Start price
Target price
Perf. (%)
?2.54
14.03.19
€4.51
04.11.19
0.00%
04.11.19

buy
Nabriva Therapeutics AG ADR

Start price
Target price
Perf. (%)
?5.99
19.10.17
€7.67
20.02.18
-17.17%
20.02.18

buy
Nabriva Therapeutics AG ADR

Start price
Target price
Perf. (%)
?6.64
19.10.17
€8.50
20.02.18
-17.17%
20.02.18

buy
Nabriva Therapeutics AG ADR

Start price
Target price
Perf. (%)
?9.37
19.09.17
€11.73
19.10.17
-36.18%
19.10.17